- American City Business Journals•8 hours ago
Exact Sciences Corp. said Wednesday that its net loss narrowed in the third quarter as heavy marketing continued to boost sales of its flagship Cologuard cancer screening product. Madison-based Exact Sciences (EXAS) reported a net loss of $37.8 million, or 36 cents per share, compared with a net loss of $42.9 million, or 45 cents per share, for the same period a year ago. Exact Sciences is a molecular diagnostics company that has developed a noninvasive DNA-based test to detect colorectal cancer.
- Associated Press•13 hours ago
The Madison, Wisconsin-based company said it had a loss of 36 cents per share. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
Exact Sciences Corporation (EXAS)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||16.80 x 300|
|Ask||16.99 x 1000|
|Day's Range||16.26 - 18.89|
|52wk Range||4.67 - 22.80|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-9.22|
|Avg Vol (3m)||3,618,890|
|Dividend & Yield||N/A (N/A)|